Study Suggests Possible Link Between Sleeping Pills and Cancer Risk

A recent study suggests a possible link between an increased risk in cancer or even death with the use of sleeping pills. Statistics show that an estimated six to ten percent of Americans currently take sleeping pills, a number that continues to increase as the public is provided with numerous options and constant advertising about the potentially harmful drugs.

The study evaluated data on 34,205 adults, with an average age of 54, including 10,531 of those adults prescribed sleeping pills. The study incorporated several different brands of pills, including Ambien, Lunesta, Restoril and Sonata. According to the Washington Post, the results showed, “people who were prescribed 18 or fewer sleeping pills a year were 3.6 times as likely to die as those who took none of the drugs; risk was 4.3 times as high for those prescribed 18 to 132 doses and 5.3 times as high for those taking more than 132 pills a year. Also, people taking the highest doses were 35 percent more likely to have developed a major cancer, not including melanoma, during that period.” (read full article)

The study shows a potential connection between the problems and pills but has yet to reach a conclusion on an absolute cause and effect. Patients should be aware of any possible risks they might face while taking sleeping pills. It is always best to consult with your doctor about any effects you may be concerned with.


If you or a loved one have ever taken a medication that lead to severe side effects or even death, don’t hesitate to contact an attorney. All patients should be properly warned about any possible side effects they may face. At Borchardt Law Firm, we have successfully represented several individuals who were not properly warned about side effects of prescription drugs and feel the work we do will continue to protect future generations of Texans. Feel free to give us a call.
Toll Free: 866.832.9300
Phone: 817.332.9300
Fax: 817.332.9301
801 Cherry St #1005
Fort Worth, Texas 76102